15 June 2026 / Medical cannabis
Cannabis medicine for chronic back pain: what Exilby's European approvals mean
Exilby has put cannabis medicine back into a serious clinical conversation: evidence, prescription access, opioid alternatives and the hard line between authorised medicines and consumer CBD.
Quick answer
Europe has approved a cannabis-based medicine, not a wellness shortcut.
Exilby, also known as VER-01, is a standardised full-spectrum Cannabis sativa flower extract developed as an oral prescription medicine for chronic low back pain.
The important point for UK readers is the category difference. A medicine approval is built on clinical trials, regulator review and prescribing controls. It does not mean ordinary CBD oils, gummies or food supplements can claim to treat back pain.
Medicine context
Exilby matters because chronic low back pain is difficult to treat well.
Chronic low back pain is not just a sore back that has lasted too long. It can involve nerve symptoms, sleep disruption, reduced movement, work absence and repeated cycles of medicines that do not suit long-term use for every patient.
That is why a non-opioid medicine with Phase 3 evidence attracts attention. The approval does not make cannabis a casual answer to back pain. It shows that a defined cannabis-derived medicine can be taken through the kind of evidence route regulators expect.
- Product
- Exilby, also known as VER-01
- Category
- Prescription cannabis-based medicine
- Indication
- Chronic low back pain in adults who need drug treatment
Important distinction
This is not the same market as consumer CBD.
Authorised medicine
A prescription medicine can be assessed for a specific medical use, with defined manufacturing, dosing, safety data, trial evidence and prescribing controls.
Consumer CBD
CBD food supplements and wellness products are regulated differently. They should not be marketed as treating pain, disease or medical conditions unless properly authorised as medicines.
A cannabis medicine approval strengthens the case for evidence. It does not weaken the need for careful claims.
Clinical evidence
The strength of the story is the trial pathway, not the cannabis label.
The published Phase 3 programme studied VER-01 in adults with chronic low back pain, including a 12-week double-blind phase and longer follow-up periods. Vertanical has also described more than 1,200 patients across pivotal randomised controlled trials supporting the approval.
For readers, the useful lesson is simple: the product is being discussed because it is a defined, standardised medicine tested in a defined patient group. Cannabis alone is not the evidence. The evidence is the trial design, the data, the safety review and the regulator's decision.
- Evidence type
- Randomised controlled Phase 3 trials
- Population
- Adults with chronic low back pain
- Next question
- How national access and reimbursement pathways respond
UK reader view
The UK question is not only approval. It is access.
Reports around the approval say a UK submission is being prepared. Even if a medicine is authorised, practical access is shaped by prescribing rules, specialist pathways, clinical guidance, reimbursement decisions and whether the evidence fits the patient group being considered.
That is why UK readers should watch the next steps carefully. A European milestone can signal momentum, but it does not automatically make a medicine available through the NHS, private prescribing or everyday pharmacy channels.
- First step
- UK medicine authorisation would need the relevant UK route
- Access step
- Clinical and economic assessment can still affect availability
- Consumer step
- Do not treat this as advice to self-medicate for back pain
Common questions
The headlines are exciting, but the details are where people can get misled.
Is Exilby the same as CBD oil?
No. Exilby is a standardised cannabis-derived medicine being developed and authorised through medicines pathways. Consumer CBD oil is normally sold as a food supplement or wellness product and cannot make the same medical claims.
Does this prove cannabis treats all back pain?
No. The evidence relates to a specific product, specific trials and a specific chronic low back pain population. It should not be stretched into a general claim about all cannabis products or all types of back pain.
Is Exilby available in the UK now?
This article should not be read as an availability announcement. UK access would depend on UK authorisation, prescribing routes and assessment processes, plus any formal company launch decisions.
Takeaway
The serious future of cannabis is evidence-led.
Exilby's European approval is important because it treats cannabis as medicine through the route medicine has to travel: defined formulation, clinical evidence, manufacturing standards, regulator scrutiny and controlled access.
For British Cannabis readers, the wider lesson is just as important. The cannabis category needs sharper language, better education and clearer boundaries between medicines, consumer CBD and unsupported medical claims.